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A B S T R A C T
Purpose: This study was undertaken to (1) measure the frequency of AED monotherapy or polytherapy
during pregnancy and AED discontinuation prior to pregnancy in a cohort of women with treated
epilepsy; and (2) describe the frequency of major congenital malformations according to maternal use of
AED during pregnancy.
Methods: A cohort of epileptic pregnant women was identiﬁed within the Quebec Pregnancy Registry
and was divided into three groups based on maternal AED use during pregnancy: AED monotherapy, AED
polytherapy and no AED use.
Results: Of the 349 pregnancies meeting eligibility criteria, 79.6% were exposed to AED monotherapy and
5.8% to polytherapy during pregnancy; 14.6% discontinued AED prior to pregnancy. The most commonly
used AEDs were carbamazepine (29.9%) and valproic acid (19.7%); the most common AED polytherapy
combination was carbamazepine combined with clobazam (2.5%). Of 111 deliveries in the group of
women on monotherapy during pregnancy, 9.9% (n = 11) were born with major congenital malformations;
in the group of women treated with polytherapy, 19.0% (n = 8 over 42) of babies had major congenital
malformations compared to 20.0% in women who discontinued AEDs prior to pregnancy.
Conclusion: This study demonstrates that the majority of women suffering from epilepsy were treated
with monotherapy rather than polytherapy during pregnancy. While most used other agents, an
important number of women continued to use valproate in pregnancy despite the long standing
evidence of its teratogenicity and increasing evidence of its neuro-toxicity to the fetus.
 2011 Published by Elsevier Ltd on behalf of British Epilepsy Association.
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Prevalence of epilepsy in pregnant women has been estimated at
0.3–0.7%.1,2 Despite the rarity of this neurologic disorder, epilepsy
presents important clinical challenges during pregnancy. In fact,
infants of women with epilepsy are known to be at increased risk of
congenital malformations believed to be due mainly to the
teratogenic effect of anti-epileptic drugs (AEDs) rather than the
underlying epileptic disorder itself.2,3 It is increasingly believed that
the disease itself plays a minor role in the etiology of congenital
malformations3–6 though it may have a greater role in the
occurrence of other adverse perinatal outcomes.1
The challenge in the treatment of women with epilepsy prior to
and during pregnancy is to balance between the beneﬁts to the
mother from maintaining an effective treatment regimen and the
risks: to the fetus from medications with recognized teratogenic* Corresponding author at: Research Center, Sainte-Justine Hospital, 3175, Coˆte-
Ste-Catherine road, Montreal, Quebec H3T 1C5, Canada.
Tel.: +1 514 345 4931x4363; fax: +1 514 345 4801.
E-mail address: anick.berard@umontreal.ca (A. Be´rard).
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doi:10.1016/j.seizure.2011.06.012potential, or to the mother from a sub-optimal management of
epilepsy.7 Monotherapy has been shown to be safer for the fetus
than polytherapy as it has been shown to be associated with a
lower risk of congenital malformations.8–11 Several studies have
also suggested that older antiepileptic drugs are more likely to
cause congenital malformations than the newer ones.12–15 In
particular, valproate has been shown to hold the greatest
teratogenic potential.4,6,11,16–18 However, data comparing the
safety of newer antiepileptic drugs use versus the older ones are
still missing. Although these data are missing, the use of second
generation AEDs are gaining popularity in a number of countries,
and the need for studies investigating the factors behind AEDs
prescription during pregnancy as well as their inﬂuence on
pregnancy outcomes have been recently raised.19
The aim of our study was therefore to estimate the frequency of
AED monotherapy or polytherapy during pregnancy and AED
discontinuation prior to pregnancy in a cohort of women with
previously diagnosed and treated epilepsy. We also described the
characteristics of women according to AED use. In addition, we
reported the frequency of major congenital malformations and
other adverse pregnancy outcomes in infants born to women with
epilepsy according to maternal use of AED during pregnancy.Epilepsy Association.
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2.1. Study setting
This study was conducted within the Quebec Pregnancy
Registry. This registry was built with the linkage of three
administrative databases: the Re´gie de l’Assurance Maladie du
Que´bec (RAMQ), Med-Echo, and the Institut de la Statistique du
Que´bec (ISQ). The RAMQ database provides prospectively collected
information on medical services dispensed to all residents of
Quebec and on prescription ﬁlling information for residents
insured by the Quebec Public Prescription Drug Insurance Plan.
This database provides data on ﬁlled prescriptions, physician-
based diagnoses (according to the International Classiﬁcation of
Diseases, ninth revision, ICD-9), physician and emergency depart-
ment visits, medical procedures and hospitalizations, and patient
and health care provider characteristics. Although RAMQ covers all
Quebec’s residents with respect to visits to the physician and the
inherent fees, hospitalizations, and procedures, not all residents
are covered by its Public Prescription Drug Insurance Plan. The
RAMQ drug plan covers individuals who are 65 years and older,
recipients of social assistance, and workers and their families
(adherents) who have no access to a private drug insurance plan
through their employers. These individuals account for approxi-
mately 42% of the overall Quebec population and 30% of pregnant
women.20 The Med-Echo database is a provincial database which
records acute care hospitalization data for all Quebec residents; it
also records gestational age (deﬁned from the ﬁrst day of the last
menstrual period to the end of pregnancy, conﬁrmed by
ultrasound) for planned and spontaneous abortions, and deliveries.
The ISQ administers the Fichier des e´ve´nements de´mographiques
that provides data on all births and deaths in Quebec, including
birth weight and gestational age. All data in the three administra-
tive databases are collected routinely and prospectively as part of
the universal health care system in Quebec. Linkage between
databases was done using subjects’ unique personal identiﬁer
(Nume´ro d’assurance maladie (NAM)). The Quebec Pregnancy
Registry is a registry including all pregnancies occurred in Quebec
between the beginning of 1998 and the end of 2003. Pregnancies
are identiﬁed in RAMQ database by a prenatal visit, and ICD-9
diagnostic or a procedure code related to pregnancy; and in Med-
Echo by a procedure code related to a pregnancy including a
planned or spontaneous abortion or a delivery (liveborn or
stillbirth). Women are followed from the beginning of pregnancy
(date of entry in the Registry), which is deﬁned as the ﬁrst day of
the last menstrual period conﬁrmed by ultrasound, until the end of
pregnancy (planned or spontaneous abortion, or delivery, which-
ever comes ﬁrst). The Quebec Pregnancy Registry has been used in
the past for epidemiological research leading to scientiﬁc articles
published in peer-reviewed medical journals.20–23 Data recorded
in the RAMQ medication database and in the Med-Echo database
have been formally compared to data in patients’ charts and
physician reviews and found to be comprehensive and valid.24
Physician-based medical diagnoses and data recorded in the ISQ
databases have been compared to information present in patients’
charts and have been found to be valid and accurate.25,26 Studies
using pregnant women insured by the RAMQ for their medications
have been shown to generate valid risk estimates.26–28
2.2. Study population
Within the Quebec Pregnancy Registry, we selected all women
who were between 15 and 45 years of age on the ﬁrst day of
gestation (date of entry in the Registry) and were continuously
insured by the RAMQ drug plan for at least 12 months prior to and
during pregnancy. The end of pregnancy was deﬁned as thecalendar date of a planned or spontaneous abortion, or a delivery. If
a woman had more than one pregnancy between 01/01/1998 and
12/31/2003, the ﬁrst pregnancy meeting eligibility criteria was
included for analysis.
2.3. Pregnant epileptic women cohort
The cohort of pregnant epileptic women accounted for all
women within the study population who had ﬁlled at least one
prescription for an AED in the 12 months prior to the ﬁrst day of
gestation and were diagnosed with epilepsy (ICD-9 codes: 3450.x)
in the 60 days preceding or following the dispensation date.
2.4. Exposure frequency of antiepileptic drug use during pregnancy
We stratiﬁed the pregnant epileptic women cohort into 3
groups based on their AED exposure during pregnancy: (1) no AED,
(2) AED monotherapy and (3) AED polytherapy (women who ﬁlled
one prescription for at least two different AEDs). To be considered
as being exposed to AED, women had to have ﬁlled at least 1
prescription for an AED during pregnancy (deﬁned as carbamaze-
pine, clobazam, clonazapam, ethosuximide, gabapentine, lamo-
trigine, phenobarbital, phenytoin, primidone, topiramate, valproic
acid or vigabatrin). The frequency of AED use before, during, and
after pregnancy was calculated. The frequency of AED use during
the 12-month period before pregnancy was calculated by dividing
the number of women exposed to AED in the 12 months prior to
pregnancy by the total number of women in the study population.
Similarly, frequency of use during the whole pregnancy – as well as
during the ﬁrst (0–14 weeks of gestation), the second (>14–26
weeks of gestation) and the third trimester (>26 weeks of
gestation) of pregnancy – was calculated. The number of women
exposed to AED in each period was divided by the number of
women in the study population at that time (depending on the
outcome of the pregnancy, some women were counted in the
denominator only in the ﬁrst or second trimester). The frequencies
of patients exposed to speciﬁc AEDs in monotherapy and
polytherapy were calculated for the total duration of pregnancy
and for each trimester separately.
2.5. Demographic and health care resource utilization
The following covariates were measured for the 3 AED exposure
groups: (1) on the ﬁrst day of gestation [maternal age, maternal
place of residence (urban vs. rural), and maternal RAMQ drug plan
status (adherent vs. welfare recipient)], (2) in the 12 months prior
to pregnancy [number of different prescribers, number of different
medication used other than AED, planned or spontaneous abortion
(yes/no), number of physician visits, number of neurologist visits,
psychiatrist visits (yes/no), emergency department visits or
hospitalization (yes/no), hypertension (ICD-9: 401.0–405.9,
362.1, 416.0, 437.2, 796.2) or use of antihypertensive drugs
(yes/no), and diabetes (ICD-9: 250.0–250.9, 271.4, 790.2) or use of
oral hypoglycemic medications or insulin (yes/no)].
2.6. Pregnancy outcomes
We obtained information on whether each pregnancy in the
cohort of pregnant epileptic women ended in a planned or
spontaneous abortion or a delivery (live birth or stillbirth). For each
live birth, we obtained information on whether the baby was
diagnosed with at least one major congenital malformation (ICD-9,
740.0–759.9, excluding the following minor malformations: 743.6,
744.1, 744.4, 744.6, 747.0, 747.5, 750.0, 752.4, 752.5, 754.6, 755.0,
755.1, 757.2–757.6, 757.8, 757.9 and 758.4) anytime during the
ﬁrst year of life. We also measured for each live birth, the status of
Table 1
Frequency of AED utilization prior to and during pregnancy.
Period considered Number
of AED
users
Total number
of pregnant
womena
Percent (95% CI)
12 months prior pregnancy 349 109 344 0.32% (0.29–0.35%)
Overall pregnancy 307 109 344 0.28% (0.25–0.31%)
1st trimester (14 weeks) 297 109 344 0.27% (0.24–0.30%)
2nd trimester
(>14 and 26 weeks)
202 90 111 0.22% (0.19–0.26%)
3rd trimester (>26 weeks) 146 64 171 0.23% (0.19–0.26%)
a At the beginning of the period considered.
Table 2
AED exposure during pregnancy with respect of prior AED exposure.
AED exposure prior
to pregnancy
AED exposure during pregnancy
Monotherapy Polytherapy Non exposed
Monotherapy (%) 191 (79.6%) 14 (5.8%) 35 (14.6%)
Polytherapy (%) 26 (23.9%) 76 (69.7%) 7 (6.4%)
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preterm gestation. A newborn was consider as SGA if his weight
adjusted for gestational age and gender was <10th percentile,
according to the Canadian gender-speciﬁc reference curves.29 The
criterion for LBW was a weight <2500 g, and preterm birth was
deﬁned as a birth occurring at gestational age <37 weeks.
2.7. Statistical analysis
To describe the study population in terms of AED exposure
during pregnancy, we presented means and proportions for
continuous and dichotomous variables, respectively. We estimated
crude odds ratios (ORs) for the associations between AED exposure
status and the risk of major congenital malformations, SGA, LBW,
and prematurity, separately, with 95% conﬁdence intervals (95%
CI) using logistic regression models. All statistical analyses were
performed using the SAS software version 9.1 (SAS Institute).
2.8. Ethics approval
This research project was approved by the Sainte-Justine’s
Hospital Ethic’s Committee and the linkage between administra-
tive databases was authorized by the ‘Commission d’Acce`s a`
l’Information du Que´bec’.
3. Results
Within the Quebec Pregnancy Registry, 109 344 pregnant
women met the inclusion criteria, and thus formed the study
population. The frequency of AED exposure in this cohort during
the 12 months prior to pregnancy was 0.32% (95%CI: 0.29%, 0.35%)
(Table 1). Frequencies of AED exposure declined signiﬁcantly
during the ﬁrst trimester compared to 12 months prior to
pregnancy (0.27% vs. 0.32%, p = 0.04), and continued to decrease
during the second (0.22%, p < 0.001), and third trimesters (0.23%,
p = 0.001) (Table 1). The number of pregnant women in the study
population dropped to 90 111 during the second trimester andTable 3
Characteristics of epileptic women with respect to AED use during pregnancy.
Variables Epileptic women (N = 349) 
Non use (N = 42) Mo
On the ﬁrst day of gestation
Maternal age, years (mean  SD) 27.5  6.4 2
Rural dwellers (n (%)) 7 (16.7) 4
Welfare recipients (n (%)) 22 (52.4) 9
In the 12 months prior to ﬁrst day of gestation
Number of different prescribers (n (%))
2 or less 14 (33.3) 2
3 or more 28 (66.7) 6
Number of different medications used other than AED (n (%))
2 or less 16 (38.1) 6
3–5 5 (11.9) 4
More than 5 21 (50.0) 10
Number of physician visits (n (%))
2 or less 3 (7.1) 1
3–5 5 (11.9) 3
More than 5 34 (81.0) 16
Psychiatrist visits (n (%)) 5 (11.9) 1
Neurologist visits (n (%))
0 10 (23.8) 6
1 15 (35.7) 8
2 or more 17 (40.5) 6
Emergency department
Visits/hospitalization (n (%)) 10 (23.8) 4
Abortion/miscarriage (n (%)) 1 (2.4) 
Hypertension (n (%)) 0 (0.0) 
Diabetes (n (%)) 0 (0.0) 64 171 in the third trimester due to planned and spontaneous
abortions, or preterm deliveries (Table 1).
The cohort of pregnant epileptic women included 349 women
exposed to AED in the 12 months prior to pregnancy (Table 2). The
majority of these women (79.6%) received AED monotherapy
during pregnancy; 5.8% received polytherapy during pregnancy,
and 14.6% were not exposed to AED at any time during gestation
(Table 2). Over the course of pregnancy we observed a reduction of
5.5% in the number of women exposed to more than one AED.
Characteristics of the cohort of pregnant epileptic women for
the three groups of AED exposure status during pregnancy are
presented in Table 3. Women in each AED exposure group were
similar with respect to age and area of residence (rural vs. urban)
on the ﬁrst day of gestation, and for all variables related to health
care services use in the 12 months prior to pregnancy except thatp-Value
notherapy (N = 217) Polytherapy (N = 90)
7.2  6.0 27.6  6.4 0.25
8 (22.1) 18 (20.0) 0.71
1 (41.9) 64 (71.1) <0.001
3 (25.6) 73 (33.6)
7 (74.4) 144 (66.4) 0.37
7 (30.9) 27 (30.0)
4 (20.3) 14 (15.6)
6 (48.8) 49 (54.4) 0.58
7 (7.8) 3 (3.3)
9 (18.0) 11 (12.2)
1 (74.2) 76 (84.4) 0.32
9 (8.8) 12 (13.3) 0.46
6 (30.4) 15 (16.7)
4 (38.7) 23 (25.6)
7 (30.9) 52 (57.8) <0.001
8 (22.2) 24 (26.7) 0.69
6 (2.8) 3 (3.3) 0.94
5 (2.3) 2 (2.2) 0.51
2 (0.9) 1 (1.1) 0.57
Table 4
Pregnancy outcomes among population of epileptic women.
Non use (N = 42) Monotherapy (N = 217) Polytherapy (N = 90) p-Valuea
Outcomes
Abortions (n (%)) 19 (45.2) 88 (40.5) 40 (44.4)
Miscarriage (n (%)) 0 (0.0) 6 (2.8) 4 (4.4)
Delivery (n (%)) 23 (54.8) 123 (56.7) 46 (51.1) 0.33
Non use (N = 21) Monotherapy (N = 123) Polytherapy (N = 42) p-Valuea
Number of deliveries at ISQ
Stillbirth (n (%)) 1 (2.4) 0 (0.0) 1 (2.4)
Live birth (n (%)) 20 (95.0) 123 (100.0) 41 (97.6) 0.10
Non use (N = 20) Monotherapy (N = 111) Polytherapy (N = 42) p-Valuea
Number of babies
Major congenital malformation (n (%)) 4 (20.0) 11 (9.9) 8 (19.0) 0.22
Low birth weightb (n (%)) 2 (10.5) 9 (8.2) 3 (7.1) 0.91
Prematurityb (<37 weeks) (n (%)) 3 (15.8) 11 (10.0) 4 (9.5) 0.73
SGAb (<10th percentile) (n (%)) 1 (5.3) 20 (18.2) 5 (11.9) 0.28
a Kruskal–Wallis test.
b Based on 171 babies (19, 110 and 42 respectively).
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others. In addition, women exposed to AED polytherapy regimens
were more likely to be welfare recipients.
During pregnancy, the three most prevalent AEDs used were
carbamazepine (29.9%), valproic acid (19.7%) and phenytoin
(11.5%). The most common drug combinations of AEDs used in
polytherapy included carbamazepine combined with clobazam
(2.5%), phenytoin (1.6%) and valproic acid (1.6%).
Of the 349 pregnant epileptic women, 192 (55.0%) pregnancies
ended with a delivery; 147 (42.1%) resulted in a planned abortion
and 10 (2.9%) in a spontaneous abortion. The linkage with the ISQ
database was possible for 173 babies (90% of all deliveries). Table 4
presents the distribution of the number of babies with major
congenital malformations diagnosed in the ﬁrst year of life, SGA,
LBW, and prematurity for the three AED exposure groups. The
proportion of babies born with major congenital malformations
was higher in the group of women with epilepsy who did not
receive AED treatment during pregnancy (20%) and in the group of
epileptic women exposed to more than one AED during pregnancy
(19%) compared to the women exposed to only one type of AED
during gestation (9.9%). LBW as well as prematurity were more
frequent among epileptic women who were not exposed to AED
during their pregnancy compared to women exposed to AED. In
contrast, the proportion of SGA was higher among epileptic
women exposed to AED than among non-exposed epileptic
women. None of the differences observed were statistically
signiﬁcant (Table 4).
4. Discussion
Using a large population-based pregnancy registry, we esti-
mated that 0.28% of pregnant women use AED during pregnancy.
This is in line with the published estimates (0.3–0.5%) of the
prevalence of epilepsy in pregnant women.1,2 The majority of
women with epilepsy in our study received monotherapy during
pregnancy suggesting that there is recognition of the importance
to both mother and fetus of continued control of the symptoms of
epilepsy during gestation. Prevalence in AED monotherapy differs
largely between regions and lies between 3.5% and 75% as recently
shown by the EURAP Study Group.19 Indeed only 12% of women
with treated epilepsy prior to pregnancy received no AEDs during
gestation. This, in combination with the observed decline in the use
of polytherapy in favour of monotherapy over the course of
pregnancy, reﬂects current understanding that on balance, and
when possible, monotherapy during pregnancy may be safest forboth mother and fetus. We observed that women who used an AED
polytherapy regimen during pregnancy were more likely to be
welfare recipients or to attend neurologist visits more frequently in
the 12-month period prior to the ﬁrst day of gestation than those
on AED monotherapy or no therapy. These characteristics may be
indicators of more severe illness among women using polytherapy
during pregnancy.
In this study, the most commonly used AED, whether in
monotherapy or polytherapy, was carbamazapine. This is consis-
tent with ﬁndings of the EURAP study which showed that in the
majority of countries (over 38 countries in total) carbamazepine is
the most commonly AED to be used during pregnancy.19 Indeed,
almost two-thirds of the AEDs used in pregnancy were the so-
called older generation AEDs. Carabamazapine has been shown to
be a comparatively safer choice for the control of epileptic seizures
during pregnancy.4,6,17,18,30 Valproate, on the other hand, has long
been shown to hold teratogenic potential if used during the ﬁrst
trimester of pregnancy. More recently it has been shown to be feto-
toxic, posing overall delayed early development31 and neuro-
developmental risks throughout pregnancy.16 That valproate was
the second most commonly used AED in monotherapy during
pregnancy and that 20% of pregnancies that proceeded under
monotherapy were exposed to valproate is a result that is of some
concern and one that warrants further study. However, studies
showed that when seizures are well controlled with valproic acid,
it is therefore difﬁcult to switch to another antiepileptic drug
before or during pregnancy. This could explain why women
continue to be treated with valproate during pregnancy.32,33 We
did not assess whether other AEDs were tried and evaluated before
pregnancy, nor did we assess whether a dose reduction prior to
pregnancy had been implemented.
In this study we deﬁned women with treated epilepsy according
to strict criteria: having ﬁlled a prescription for an AED within 60
days of a diagnostic code for epilepsy in the year prior to pregnancy.
Both criteria had to be fulﬁlled in order to meet eligibility
requirements for the study. This ensured that the study was
conducted among women with documented and treated epilepsy. It
is nevertheless possible that some women with long standing
treated epilepsy could have been excluded if they continued on their
AEDs with no physician visit within 60 days of having ﬁlled a
prescription. We expect that the number of women excluded in
this way would be low, and have no reason to believe that
their pregnancy experiences or outcomes would be different from
the women included in the study. Our choice resulted in a speciﬁc
cohort of epileptic women who became pregnant.
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maternal AED exposure. The number of women in each group was
small, leading to a lack of statistical power needed for robust
interpretation of these results. Proportion of major congenital
malformations was higher among women who were on polytherapy
compared to women on monotherapy which is consistent with
previous ﬁndings.11 However, this difference was not statistically
signiﬁcant. Nevertheless, it was of interest that in this study women
with epilepsy who used no AEDs during pregnancy and those who
used polytherapy during pregnancy delivered a similar proportion of
infants born with major congenital malformations, nearly double of
those who used monotherapy. In fact, 25–30% of women with
epilepsy experience an increase in their seizure activity during
pregnancy.34 Therefore, the higher risk of congenital malformation
in the untreated group compared to the group treated with
monotherapy could be explained by the maternal seizure disorder
itself. In fact, the rate of malformation is comparable between the
untreated group and the group treated with polytherapy which
could suggest that the best way to control the disease and protect the
baby would be, similarly to what was reported in the literature,
having a monotherapy treatment rather than not treating or treating
with two or more antiepileptic drugs.35 The frequency of planned
abortions was higher in the study (42%) compared to the planned
abortion prevalence among non-epileptic women of the overall
Quebec Pregnancy Registry (36.2%) likely due to the particular
concerns with pregnancy in epileptic women. Similar proportions of
pregnancies were terminated by planned abortions in the three AED
exposure categories. On the other hand a higher proportion of babies
were born SGA following maternal monotherapy during pregnancy
than under polytherapy or no AED use during pregnancy.
The strengths of our study include its large sample size,
accurate information on ﬁlled medications without reliance on
maternal recall, and physician-based diagnostics or procedures
related to adverse pregnancy outcomes that are prospectively and
routinely collected limiting the potential for detection bias.
Gestational age, previously validated,26 was obtained from
hospital charts, which enabled us to calculate exact timing of
AED exposure during pregnancy. Finally, diagnoses of major
congenital malformations have previously been validated.36
Limitations of this study include the use of exposure data based
on prescription ﬁllings, which might not necessarily reﬂect actual
intake. However, we hypothesize that women who ﬁlled a
prescription for an AED took at least one dose since within the
Quebec drug plan they need to pay in part for their medications.
Therefore, given the design of our study, this would not invalidate
our ﬁndings. Also, we were not able to take into account the type
and severity of epilepsy, not the dosage of the different AEDs used
in our cohort. In addition, since we are using administrative
databases, information on potential confounding variables such as
smoking and maternal obesity was not available. However, given
that we have performed multivariate analyses among pregnant
women with epilepsy, our comparison groups tend to be similar in
terms of lifestyles, thus decreasing the likelihood of such a bias.
Also, we feel conﬁdent that although our sample consisted of
women from a relatively disadvantaged socioeconomic back-
ground, we do not think that this would bias our results. In fact,
socioeconomic status was found to be an effective modiﬁer in the
Quebec Pregnancy Registry but not a confounder.27 Moreover,
although previous studies associated incidence of epilepsy with
age and socioeconomic status,37,38 to our knowledge, no studies
have shown association between socio-economic status and
severity of epilepsy. Therefore we do not believe that being
covered RAMQ drug plan is associated with the degree of severity
of the disease. Finally, the fact that our study population covers
only 30% of pregnant women in Quebec does not affect the validity
of our ﬁndings though it might inﬂuence generalisability.This study demonstrates that the majority of women with
epilepsy were treated with monotherapy rather than polytherapy
during pregnancy. While most used other agents, an important
number continued to use valproate in pregnancy in the face of long
standing evidence of its teratogenicity and increasing evidence of
its feto-toxicity. This ﬁnding raises a concern and a need of future
studies investigating the reasons behind valproate use in
pregnancy and other possible alternative treatments.
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